S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Terumo (TRUMY) Stock Forecast & Price Target

$38.23
+0.48 (+1.27%)
(As of 02/22/2024 ET)

Terumo Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
2/23/23 to 2/23/24
1 Month Ago
1/24/23 to 1/24/24
3 Months Ago
11/25/22 to 11/25/23
1 Year Ago
2/23/22 to 2/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Terumo Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TRUMY and its competitors with MarketBeat's FREE daily newsletter.


TRUMY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TRUMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Terumo Stock vs. The Competition

TypeTerumoMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside1,075.58% Upside7.77% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/14/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
3/31/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:54 AM ET.












TRUMY Price Target - Frequently Asked Questions

What is Terumo's consensus rating?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Terumo stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for TRUMYthe . Learn more on TRUMY's analyst rating history.

Do Wall Street analysts like Terumo more than its competitors?

Analysts like Terumo less than other Medical companies. The consensus rating score for Terumo is 2.50 while the average consensus rating score for medical companies is 2.68. Learn more on how TRUMY compares to other companies.


Stock Ratings Reports and Tools

This page (OTCMKTS:TRUMY) was last updated on 2/23/2024 by MarketBeat.com Staff